PCSK9 Inhibitors-A New Hope for Dyslipidemia in HIV.

Journal

Cardiology in review

ISSN: 1538-4683

Titre abrégé: Cardiol Rev

Pays: United States

ID NLM: 9304686

Informations de publication

Date de publication:
29 Nov 2023

Historique:

medline: 29 11 2023

pubmed: 29 11 2023

entrez: 29 11 2023

Statut: aheadofprint

Résumé

Cardiovascular disease has become increasingly prevalent in the HIV population. Antiretroviral therapy and HIV itself independently increase the risk of dyslipidemia. While statins are currently the predominant therapy to treat dyslipidemia in HIV patients, drug-drug interactions and adverse drug events can limit their use. Proprotein convertase subtilisin/kexin type 9 inhibitors have shown promising results in preliminary trials by significantly reducing low density lipoprotein and other atherogenic lipid levels. They should be considered as an early intervention alongside statins in HIV patients with dyslipidemia.

Identifiants

DOI: 10.1097/CRD.0000000000000587 PMID: 38019027

pubmed: 38019027

doi: 10.1097/CRD.0000000000000587

pii: 00045415-990000000-00177

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Déclaration de conflit d'intérêts

Disclosure: The authors have no conflicts of interest to report.

Références

Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138:1100–1112.

Hsue PY, Waters DD. Time to recognize HIV infection as a major cardiovascular risk factor. Circulation. 2018;138:1113–1115.

Funderburg NT, Mehta NN. Lipid abnormalities and inflammation in HIV inflection. Curr HIV/AIDS Rep. 2016;13:218–225.

Ekoru K, Young EH, Dillon DG, et al. HIV treatment is associated with a two-fold higher probability of raised triglycerides: pooled analyses in 21 023 individuals in sub-Saharan Africa. Glob Health Epidemiol Genom. 2018;3:e7.

Leyes P, Cofan M, González-cordón A, et al. Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. AIDS. 2018;32:1309–1316.

Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab. 1993;76:1423–1427.

D’ascenzo F, Cerrato E, Calcagno A, et al. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis. 2015;240:197–204.

Stone GW, Maehara A, Lansky AJ, et al.; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–235.

Aberg JA. Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am. 2009;38:207–222. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753589/. Published March 2009. Accessed March 24, 2023.

Boccara F, Ghislain M, Meyer L, et al.; ANRS-COPANA Study Group. Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort. AIDS. 2017;31:2367–2376.

Leander K, Mälarstig A, Van’t hooft FM, et al. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors. Circulation. 2016;133:1230–1239.

Leucker TM, Weiss RG, Schär M, et al. Coronary endothelial dysfunction is associated with elevated serum PCSK9 levels in people with HIV independent of low-density lipoprotein cholesterol. J Am Heart Assoc. 2018;7:e009996.

A multicenter, randomized, double-blind, placebo... - clinicaltrials.gov. Available at: https://clinicaltrials.gov/ProvidedDocs/06/NCT03717506/Prot_SAP_000.pdf. Accessed March 25, 2023.

Hajar R. PCSK 9 inhibitors: a short history and a new era of lipid-lowering therapy. Heart Views. 2019;20:74–75. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686613/. Published 2019. Accessed March 24, 2023.

Coronary endothelial dysfunction is associated with elevated serum. Available at: https://www.ahajournals.org/doi/10.1161/JAHA.118.009996. Accessed March 25, 2023.

Weintraub WS, Gidding SS. PCSK9 inhibitors: a technology worth paying for? Pharmacoeconomics. 2016;34:217–220. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816976/#:~:text=for%20homozygous%20FH.-,The%20drugs%20are%20expensive%2C%20costing%20over%20%2412%2C000%20a%20year.,it%20is%20a%20good%20value. Accessed June 16, 2023.